Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review
| العنوان: | Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review |
|---|---|
| المؤلفون: | Donato,Eva Maria, Fernández-Zarzoso,Miguel, Hueso,José Antonio, de la Rubia,Javier |
| المصدر: | OncoTargets and Therapy. |
| بيانات النشر: | Dove Press, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | hemic and lymphatic diseases, OncoTargets and Therapy |
| الوصف: | Eva M Donato,1 Miguel Fernández-Zarzoso,1 Jose Antonio Hueso,1 Javier de la Rubia1,2 1Hematology Service, University Hospital Doctor Peset, Valencia, Spain; 2Department of Internal Medicine, Universidad Católica de Valencia “San Vicente Mártir,” Valencia, Spain Abstract: Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) account for ~10% and 2%–3% of all cases of lymphoid neoplasms, respectively. Up to 30% of patients with HL are refractory or relapse after first-line therapy, and elderly patients with HL represent a subgroup of patients with suboptimal responses to the currently available treatments. Five-year overall survival for ALCL patients is 50%–80% with conventional chemotherapy. Therefore, new therapeutic approaches are needed for these groups of patients. Brentuximab vedotin is a chimeric IgG1 anti-CD30 antibody–drug conjugate that has all the features that are necessary to make a substantive difference with the standard therapies in patients with HL and ALCL: a novel mechanism of action, single-agent activity, non-cross-resistance, and safety both in the relapsed-refractory and in the front-line setting. This review provides an update of the results of the most relevant clinical trials including brentuximab vedotin for patients with HL and ALCL conducted to date. Keywords: anaplastic large-cell lymphoma, anti-CD30 antibody, brentuximab vedotin, Hodgkin lymphoma |
| وصف الملف: | text/html |
| اللغة: | English |
| تدمد: | 1178-6930 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=dovemedicalp::fdea3c92dd429143be8ca1fcbb95f80dTest https://www.dovepress.com/brentuximab-vedotin-in-hodgkin-lymphoma-and-anaplastic-large-cell-lymp-peer-reviewed-article-OTTTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.dovemedicalp..fdea3c92dd429143be8ca1fcbb95f80d |
| قاعدة البيانات: | OpenAIRE |
| ResultId |
1 |
|---|---|
| Header |
edsair OpenAIRE edsair.dovemedicalp..fdea3c92dd429143be8ca1fcbb95f80d 829 3 unknown 829.45166015625 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dovemedicalp..fdea3c92dd429143be8ca1fcbb95f80d&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
|
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Donato%2CEva+Maria%22">Donato,Eva Maria</searchLink><br /><searchLink fieldCode="AR" term="%22Fernández-Zarzoso%2CMiguel%22">Fernández-Zarzoso,Miguel</searchLink><br /><searchLink fieldCode="AR" term="%22Hueso%2CJosé+Antonio%22">Hueso,José Antonio</searchLink><br /><searchLink fieldCode="AR" term="%22de+la+Rubia%2CJavier%22">de la Rubia,Javier</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => <i>OncoTargets and Therapy</i>. ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Dove Press, 2018. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2018 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22hemic+and+lymphatic+diseases%22">hemic and lymphatic diseases</searchLink><br /><searchLink fieldCode="DE" term="%22OncoTargets+and+Therapy%22">OncoTargets and Therapy</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Eva M Donato,1 Miguel Fernández-Zarzoso,1 Jose Antonio Hueso,1 Javier de la Rubia1,2 1Hematology Service, University Hospital Doctor Peset, Valencia, Spain; 2Department of Internal Medicine, Universidad Católica de Valencia “San Vicente Mártir,” Valencia, Spain Abstract: Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) account for ~10% and 2%–3% of all cases of lymphoid neoplasms, respectively. Up to 30% of patients with HL are refractory or relapse after first-line therapy, and elderly patients with HL represent a subgroup of patients with suboptimal responses to the currently available treatments. Five-year overall survival for ALCL patients is 50%–80% with conventional chemotherapy. Therefore, new therapeutic approaches are needed for these groups of patients. Brentuximab vedotin is a chimeric IgG1 anti-CD30 antibody–drug conjugate that has all the features that are necessary to make a substantive difference with the standard therapies in patients with HL and ALCL: a novel mechanism of action, single-agent activity, non-cross-resistance, and safety both in the relapsed-refractory and in the front-line setting. This review provides an update of the results of the most relevant clinical trials including brentuximab vedotin for patients with HL and ALCL conducted to date. Keywords: anaplastic large-cell lymphoma, anti-CD30 antibody, brentuximab vedotin, Hodgkin lymphoma ) Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => text/html ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1178-6930 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=dovemedicalp::fdea3c92dd429143be8ca1fcbb95f80d" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=dovemedicalp::fdea3c92dd429143be8ca1fcbb95f80d</link><br /><link linkTarget="URL" linkTerm="https://www.dovepress.com/brentuximab-vedotin-in-hodgkin-lymphoma-and-anaplastic-large-cell-lymp-peer-reviewed-article-OTT" linkWindow="_blank">https://www.dovepress.com/brentuximab-vedotin-in-hodgkin-lymphoma-and-anaplastic-large-cell-lymp-peer-reviewed-article-OTT</link> ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => OPEN ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.dovemedicalp..fdea3c92dd429143be8ca1fcbb95f80d ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => hemic and lymphatic diseases
[Type] => general
)
[1] => Array
(
[SubjectFull] => OncoTargets and Therapy
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Donato,Eva Maria
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Fernández-Zarzoso,Miguel
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hueso,José Antonio
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => de la Rubia,Javier
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 06
[M] => 08
[Type] => published
[Y] => 2018
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 11786930
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsair
)
[2] => Array
(
[Type] => issn-locals
[Value] => edsairFT
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => OncoTargets and Therapy
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |